Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy | Nature Reviews Immunology
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Actemra Infusion - NPS MedicineWise
![The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/10322/1/fig-3-full.png "The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]")
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]
Actemra | Uses, Safety Info & Comparison to Other RA Drugs
About ACTEMRA® (tocilizumab) Treatment Info for Healthcare Professionals
Treatment of Rheumatoid Arthritis with Biological Agents | IntechOpen
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia | SpringerLink
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? | Medicine
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19 - ScienceDirect
Frontiers | Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis | Pharmacology
Frontiers | Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19 | Pharmacology
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT) - Clinical Microbiology and Infection
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up - eClinicalMedicine
How is Actemra® (tocilizumab) for GCA believed to work?
Tocilizumab in the treatment of adult rheumatoid arthritis | Immunotherapy
Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis | Infectious Diseases of Poverty | Full Text
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | SpringerLink
Outlook of IL-6 signaling blockade for COVID-19 pneumonia | Inflammation and Regeneration | Full Text
Actemra (Tocilizumab) Shortage Is Still Affecting Rheumatology Patients
Clinical experience of IL-6 blockade in rheumatic diseases—Implications on IL-6 biology and disease pathogenesis - ScienceDirect
Figure 5 | The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Mechanism of action of tocilizumab in RA (bathtub theory). Notes: The... | Download Scientific Diagram
IJMS | Free Full-Text | Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence | HTML
